The prevention of breast cancer.
The case for treating women at high risk of breast cancer with the anti-oestrogen tamoxifen is presented. This is a logical extension of a screening programme and is scientifically based on the effectiveness of tamoxifen in established disease, the relation between free oestradiol (and other hormone-related factors) to the risk of breast cancer, and the lack of side-effects from tamoxifen treatment. Choice of a high-risk group is critical; a specific trial protocol is outlined.
Cuzick
J
J
Wang
D Y
DY
Bulbrook
R D
RD
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000235:genetics / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D005260:Female; D005348:Fibrocystic Breast Disease / Q000150:complications; D006801:Humans; D008327:Mammography; D008403:Mass Screening; D008423:Maternal Age; D008593:Menopause; D008875:Middle Aged; D010298:Parity; D012738:Sex Hormone-Binding Globulin / Q000378:metabolism; D013629:Tamoxifen / Q000627:therapeutic use
D012738:Sex Hormone-Binding Globulin; D013629:Tamoxifen